Smoldering Multiple Myeloma (SMM) — an intermediate plasma cell disorder occupying the continuum between the pre-malignant state of Monoclonal Gammopathy of Undetermined Significance and symptomatic active multiple myeloma, defined by the presence of a serum monoclonal protein at or exceeding 3 g/dL or urine monoclonal protein exceeding 500 mg/24 hours, or bone marrow clonal plasma cells comprising 10–60% of the cellular marrow, in the absence of myeloma-defining events (hypercalcemia, renal insufficiency, anemia, lytic bone lesions, or any of the three biomarkers of near-inevitable progression: bone marrow plasma cells ≥60%, serum free light chain ratio ≥100, or MRI-detected focal lesions ≥2 — each of which upgrades a patient to active multiple myeloma requiring treatment even without CRAB criteria), characterized by a substantially higher progression risk than MGUS at approximately 10% per year in the first 5 years (declining thereafter as the highest-risk patients have progressed), risk-stratified by multiple competing models including the Mayo 2018 criteria identifying ultra-high-risk SMM patients with M-protein ≥2 g/dL, bone marrow plasma cells ≥20%, and serum free light chain ratio ≥20 whose 2-year progression risk exceeds 50%, the IMWG 20/2/20 model, and the PETHEMA model incorporating plasma cell immunophenotypic aberrancy by flow cytometry; distinguished from active myeloma by the absence of CRAB end-organ damage and myeloma-defining biomarker events but distinguished from MGUS by the higher M-protein quantity or plasma cell burden that places SMM patients in the highest-risk category of plasma cell disorder surveillance where 6-month monitoring intervals, whole-body MRI or PET-CT imaging, and increasingly early treatment for ultra-high-risk patients with daratumumab-lenalidomide (AQUILA trial) define the modern clinical standard; presenting without symptoms in most patients but requiring systematic bone marrow evaluation, whole-body imaging, and serial biomarker trending to distinguish true SMM from active myeloma with unrecognized end-organ damage and to identify the subgroup of ultra-high-risk patients in whom early therapeutic intervention before end-organ damage is now supported by clinical trial evidence demonstrating delayed progression to symptomatic myeloma and potential improvement in long-term outcomes.
SMM technology platforms — whether supporting myeloma programs coordinating serial surveillance and risk stratification (managing SPEP result documentation with M-protein quantification trending across sequential 3–6-month measurements; serum protein immunofixation isotype characterization; serum free light chain kappa, lambda, and kappa/lambda ratio calculation; 24-hour urine protein electrophoresis and immunofixation documentation; complete blood count, creatinine, calcium, LDH, and albumin trending; bone marrow biopsy documentation including plasma cell percentage by differential and CD138 immunohistochemistry, flow cytometric immunophenotyping of plasma cell aberrancy, FISH cytogenetic risk documentation covering del17p, t(4;14), t(14;16), and 1q21 amplification; whole-body MRI lesion characterization and focal lesion counting for the critical myeloma-defining event threshold of ≥2 focal lesions; PET-CT staging for FDG-avid lesion detection and SMM versus active myeloma bone involvement assessment), risk stratification and escalation platforms (Mayo 2018 risk score calculation integrating M-protein, bone marrow plasma cells, and free light chain ratio; 20/2/20 IMWG score documentation; progression velocity monitoring with delta M-protein calculation triggering escalated assessment intervals; whole-body MRI comparison across serial studies for new focal lesion development; AQUILA eligibility assessment for ultra-high-risk SMM patients considering daratumumab-lenalidomide early intervention), treatment initiation platforms for ultra-high-risk patients entering early treatment protocols (daratumumab-lenalidomide-dexamethasone prescribing and administration records; clinical trial enrollment documentation for SMM intervention studies; infusion administration records; response assessment documentation to treatment using IMWG response criteria adapted for SMM-to-treatment transition), and long-term progression event monitoring platforms (CRAB criteria surveillance documentation; myeloma-defining biomarker event monitoring; progression-to-active-myeloma reclassification workflows) — must maintain the availability and performance standards that SMM's high-progression-risk biology, multimodality surveillance intensity, risk-stratification precision, and emerging early-treatment paradigm demand. This guide explains why SMM care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the high-stakes, imaging-intensive, risk-stratification-driven nature of modern SMM management.
Why SMM Care Tech Platforms Require Specialized Monitoring Attention
SMM management is defined by the diagnostic imperative of distinguishing true SMM from active myeloma with unrecognized end-organ damage (where whole-body MRI, PET-CT, and bone marrow plasma cell precise quantification resolve the classification), the exceptional progression-risk heterogeneity across SMM patients requiring individualized risk stratification to identify the ultra-high-risk minority who benefit from early intervention versus the intermediate- and low-risk majority who remain in active surveillance, the 6-month monitoring intensity that creates a high-frequency clinical encounter cadence where platform availability on every surveillance visit is clinically consequential, and the emerging early-treatment paradigm that requires treatment initiation platforms reliably integrated with surveillance monitoring. Technology failures create disruptions calibrated to the imaging, risk stratification, and treatment-readiness consequences of SMM's high-stakes progression monitoring.
Whole-body MRI and imaging platforms are essential for myeloma-defining event detection. Whole-body MRI is the gold standard for detecting focal bone marrow lesions — where the identification of ≥2 focal lesions greater than 5 mm each upgrades SMM to active myeloma requiring immediate treatment regardless of CRAB criteria, where diffuse bone marrow infiltration pattern on MRI independently predicts high progression risk, and where the comparison of sequential whole-body MRI studies at 6–12-month intervals detects new focal lesion development as the primary imaging progression signal. Platforms managing whole-body MRI scheduling, focal lesion documentation and counting, lesion characterization (size, location, diffusion restriction pattern), and serial comparison imaging are essential to the surveillance workflow where an imaging platform failure during a scheduled 6-month whole-body MRI review can delay recognition of a myeloma-defining imaging event. Monitor whole-body MRI and PET-CT imaging platforms at 1-minute intervals during business hours.
SPEP and free light chain trending platforms monitor the quantitative biomarker progression trajectory. Serial SPEP with M-protein quantification, serum immunofixation, serum free light chain ratio, and 24-hour urine protein electrophoresis provide the quantitative biomarker surveillance backbone where a rising M-protein from 3.1 g/dL to 3.6 g/dL to 4.4 g/dL across three 6-month assessments represents a velocity signal that, combined with concurrent free light chain ratio rise above 20, constitutes ultra-high-risk biomarker progression requiring bone marrow biopsy re-evaluation and myeloma-defining event exclusion. Monitor SPEP and free light chain trending platforms at 1-minute intervals during business hours.
Bone marrow pathology platforms resolve the SMM-to-active myeloma reclassification boundary. Bone marrow biopsy documenting plasma cell percentage precisely — where a plasma cell fraction crossing the 60% threshold is a myeloma-defining biomarker event requiring immediate treatment initiation regardless of other criteria — requires pathology platforms reliably available to document CD138-stained plasma cell quantification, flow cytometric immunophenotyping confirming clonality and aberrancy, and FISH cytogenetic high-risk features including del17p and t(4;14) that inform risk stratification and treatment selection at the boundary between surveillance and active therapy. Monitor bone marrow pathology platforms at 1-minute intervals during business hours.
Risk stratification documentation platforms determine surveillance intensity and treatment eligibility. The Mayo 2018 risk model, IMWG 20/2/20 criteria, and PETHEMA model each integrate M-protein quantity, plasma cell percentage, serum free light chain ratio, and immunophenotypic aberrancy into a risk classification that determines surveillance frequency (6 months for intermediate/high-risk, potentially shorter for ultra-high-risk) and treatment eligibility under emerging early-intervention protocols. Platform failures affecting risk score calculation, documentation, or integration with surveillance scheduling logic can result in under-surveillance of high-risk patients or misinformed treatment eligibility assessment. Monitor risk stratification documentation platforms at 1-minute intervals during business hours.
Early treatment initiation platforms serve an expanding ultra-high-risk SMM population. The AQUILA trial demonstrating improved overall survival with daratumumab-lenalidomide in ultra-high-risk SMM, and multiple ongoing clinical trials for early SMM intervention, mean that an increasing proportion of SMM patients are entering active treatment rather than surveillance-only management. Treatment initiation platforms managing daratumumab and lenalidomide prescribing, infusion scheduling, oral agent dispensing, IMWG response assessment documentation, and clinical trial data entry must be reliably available for a population transitioning from surveillance into high-intensity treatment. Monitor treatment initiation and infusion platforms at 1-minute intervals during clinical hours.
What to Monitor on a SMM Care Tech Platform
SPEP, Immunofixation, and Free Light Chain Trending
Monitor SPEP result documentation with M-protein quantification (g/dL) and serial trending, delta M-protein calculation across sequential measurements with velocity assessment, serum protein immunofixation isotype documentation (IgG, IgA, IgM, IgD, free kappa, free lambda), serum free light chain kappa and lambda quantification with kappa/lambda ratio calculation and comparison to the myeloma-defining threshold of ≥100, 24-hour urine protein electrophoresis and immunofixation results, LDH, albumin, calcium, creatinine, and hemoglobin documentation integrated with M-protein trending, and alert generation for biomarker values crossing myeloma-defining event thresholds at 1-minute intervals during business hours. Alert immediately — SPEP and free light chain trending platform failures during scheduled 6-month surveillance encounters prevent the quantitative biomarker assessment whose velocity and threshold determinations are the surveillance system's primary non-imaging progression signals.
Bone Marrow Pathology and Cytogenetics
Monitor bone marrow core biopsy documentation (plasma cell percentage by morphology, CD138 immunohistochemical count and percentage with hot-spot area documentation, cellularity, fat fraction, infiltration pattern assessment), flow cytometric immunophenotyping of plasma cells (CD138/CD38 co-expression for plasma cell identification; CD56, CD19, CD45, CD27, CD20, CD117 aberrancy characterization; kappa/lambda restriction assessment; percentage of aberrant plasma cells within total plasma cell gate), FISH cytogenetic risk documentation (del17p, t(4;14), t(14;16), del13q, 1q21 gain, hyperdiploidy), pathology report integration into SMM risk stratification records, and reclassification documentation when bone marrow plasma cells cross 60% requiring immediate treatment initiation at 1-minute intervals during business hours. Alert immediately — bone marrow pathology platform failures at the 6-month surveillance assessment delay the plasma cell percentage documentation whose precision determines whether the SMM boundary remains intact or has been crossed.
Whole-Body MRI and PET-CT Imaging Management
Monitor whole-body MRI scheduling (1.5T or 3T whole-body protocol with STIR and diffusion-weighted sequences), focal lesion documentation and size measurement (lesions ≥5 mm documented with location, T1/STIR signal characteristics, and diffusion restriction), lesion count tracking against the myeloma-defining event threshold of ≥2 focal lesions, diffuse infiltration pattern characterization (normal, focal, diffuse, variegated, salt-and-pepper), serial comparison imaging with new lesion identification workflows, PET-CT scheduling for FDG-avid lesion detection when MRI is contraindicated or for metabolic activity characterization, and imaging report integration into SMM staging records at 1-minute intervals during business hours. Alert immediately — imaging platform failures delay the focal lesion documentation that may identify a myeloma-defining event requiring immediate treatment initiation in a patient presenting for routine surveillance.
Risk Stratification and Progression Velocity Documentation
Monitor Mayo 2018 risk score calculation (M-protein ≥2 g/dL, bone marrow plasma cells ≥20%, free light chain ratio ≥20 — each one point, total score 0/1/2/3 driving low/intermediate/high/ultra-high-risk classification), IMWG 20/2/20 risk documentation, PETHEMA flow cytometric model documentation (proportion of aberrant plasma cells within total plasma cell gate, angiogenesis ratio), surveillance interval generation based on current risk classification (6 months for intermediate/high-risk), progression velocity documentation with trend alerts for M-protein rises exceeding 0.5 g/dL per 6 months or free light chain ratio rises crossing 20, treatment eligibility assessment for ultra-high-risk SMM patients with evidence-based early intervention criteria, and clinical trial enrollment documentation at 1-minute intervals during business hours.
Early Treatment Administration (Ultra-High-Risk SMM)
Monitor daratumumab and daratumumab-rHuPH20 prescribing and pharmacy verification records, lenalidomide oral prescribing and REMs dispensing documentation (lenalidomide REMS risk assessment and dispensing authorization), dexamethasone prescribing records, daratumumab infusion administration documentation and infusion reaction management records, IMWG response assessment at scheduled intervals (VGPR, PR, MR, SD documentation adapted from active myeloma criteria), MRD negativity assessment by next-generation flow or sequencing for patients achieving deep response, and clinical trial data entry for SMM intervention protocols at 1-minute intervals during infusion sessions and clinical hours.
CRAB Criteria Surveillance and Myeloma-Defining Event Monitoring
Monitor calcium documentation with alert thresholds for hypercalcemia (corrected calcium >11 mg/dL triggering active myeloma reclassification assessment), creatinine and eGFR trending with acute kidney injury alert thresholds (creatinine >2 mg/dL), hemoglobin monitoring with anemia documentation (hemoglobin <10 g/dL triggering myeloma-defining event evaluation), bone pain symptom documentation and skeletal survey or whole-body CT ordering for lytic lesion assessment, myeloma-defining biomarker event documentation (plasma cells ≥60%, FLC ratio ≥100, MRI focal lesions ≥2), and SMM-to-active-myeloma reclassification workflow initiation with immediate oncology notification at 1-minute intervals during clinical hours. Alert immediately — CRAB criteria monitoring platform failures delay recognition of the progression event requiring urgent treatment initiation in a patient previously managed with surveillance.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. SMM programs coordinate across myeloma oncology, hematopathology, musculoskeletal radiology (whole-body MRI interpretation), nuclear medicine (PET-CT), clinical pharmacy (lenalidomide REMS, daratumumab), and clinical trials — authentication failures simultaneously block every member of the multidisciplinary team whose 6-month surveillance coordination and risk stratification decisions depend on continuous integrated platform access.
SSL Certificates
Monitor SSL certificate expiry across all SMM surveillance portals, imaging management platforms, bone marrow pathology systems, risk stratification tools, and patient-facing portals. Certificate errors disrupt the integrated surveillance workflow connecting myeloma oncologists, radiologists, hematopathologists, and clinical pharmacists in the high-frequency 6-month SMM monitoring cadence.
HIPAA and Oncology Data Privacy Considerations
SMM technology platforms handle sensitive PHI including pre-malignant cancer diagnosis records with insurance implications, bone marrow biopsy and cytogenetic risk documentation, whole-body MRI focal lesion records with skeletal anatomy detail, serum free light chain ratio data identifying ultra-high-risk individuals, clinical trial enrollment records, daratumumab and lenalidomide prescribing documentation (lenalidomide is REMS-regulated), and myeloma-defining event reclassification records establishing the transition from surveillance to active cancer treatment. HIPAA Security Rule requirements for PHI availability and integrity apply across all components managing SMM surveillance and treatment PHI.
For platforms managing lenalidomide REMS documentation — where the Revlimid REMS program requires documented pregnancy testing, patient counseling, and prescriber and pharmacy certification with records maintained to FDA standards — regulatory compliance obligations under REMS program requirements intersect with HIPAA PHI protection. Availability monitoring provides operational documentation supporting both HIPAA Security Rule administrative safeguard compliance and REMS program record availability requirements.
Alerting Strategy for SMM Care Tech Platforms
Immediate 24/7 alert: Authentication endpoints. SMM programs with active early-treatment patients receiving daratumumab infusions require round-the-clock access.
Immediate business-hours alert: SPEP and free light chain trending, bone marrow pathology documentation, whole-body MRI and PET-CT imaging management, risk stratification documentation, and CRAB criteria surveillance. Alert the moment any of these fail during the 6-month surveillance encounter where M-protein velocity, imaging progression, and myeloma-defining event thresholds are being assessed.
Immediate during infusion sessions: Daratumumab administration platforms, infusion reaction documentation, and lenalidomide REMS dispensing for ultra-high-risk SMM patients in early treatment.
Sustained-failure alert (10–15 minutes): Clinical trial data entry platforms, IMWG response assessment documentation for treated SMM, and long-term surveillance scheduling.
30-day advance warning: SSL certificates across all SMM surveillance and clinical trial domains.
Vigilmon's multi-region monitoring confirms SMM platform availability from the geographies where comprehensive cancer centers and academic myeloma programs with high-risk SMM surveillance expertise and early-treatment clinical trial access concentrate — critical for platforms serving patients traveling to specialized myeloma centers for ultra-high-risk SMM management.
Status Page for SMM Care Team Communication
A real-time status page gives myeloma oncologists reviewing 6-month surveillance results, musculoskeletal radiologists interpreting whole-body MRI focal lesion comparisons, hematopathologists issuing plasma cell percentage quantification reports, clinical pharmacists verifying lenalidomide REMS compliance for ultra-high-risk SMM patients entering early treatment, and clinical trials coordinators documenting enrollment and response data immediate platform visibility without requiring inbound IT support contact. During an imaging platform outage when a myeloma specialist is reviewing the whole-body MRI comparison for a high-risk SMM patient whose prior study showed two 4-mm focal lesions and whose current study must be evaluated for lesion growth crossing the 5-mm myeloma-defining event threshold — where a positive finding requires same-day treatment initiation discussion — a status page enables immediate clinical contingency activation ensuring that critical imaging review is not delayed by platform unavailability.
Include the status page URL in myeloma program downtime procedures, SMM surveillance clinic emergency workflows, daratumumab infusion suite emergency protocols, and lenalidomide REMS documentation contingency procedures.
Vigilmon Setup for SMM Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | SPEP / immunofixation / free light chain trending | 1 min | Slack + PagerDuty (business hours) | | Bone marrow pathology / FISH cytogenetics | 1 min | Slack + PagerDuty (business hours) | | Whole-body MRI / PET-CT imaging management | 1 min | Slack + PagerDuty (business hours) | | Risk stratification / progression velocity | 1 min | Slack + PagerDuty (business hours) | | CRAB criteria / myeloma-defining event monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Daratumumab infusion / lenalidomide REMS (active treatment) | 1 min | Slack + PagerDuty (infusion hours) | | Clinical trial data entry / IMWG response assessment | 2 min | Slack (business hours) | | Long-term surveillance scheduling | 2 min | Slack (sustained failure 15 min) | | Patient portal / surveillance results access | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure SPEP, immunofixation, and free light chain trending platforms with immediate business-hours alerting
- Add bone marrow pathology and FISH cytogenetic documentation platforms with immediate business-hours alerting
- Configure whole-body MRI and PET-CT imaging management with immediate business-hours alerting
- Add risk stratification and progression velocity documentation with immediate business-hours alerting
- Configure CRAB criteria and myeloma-defining event monitoring with immediate clinical-hours alerting
- Add daratumumab infusion and lenalidomide REMS platforms for ultra-high-risk patients with immediate infusion-hours alerting
- Configure clinical trial data entry and response assessment with business-hours alerting
- Add surveillance scheduling and patient portal monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all myeloma surveillance, imaging, pathology, and clinical trial domains
- Add the status page URL to myeloma clinic downtime procedures, SMM surveillance emergency workflows, and daratumumab infusion emergency protocols
Conclusion
SMM technology platforms are embedded in the most consequential surveillance boundary in plasma cell disorder management — where the same hematologist who documented a patient's first SMM diagnosis with M-protein 3.4 g/dL, bone marrow plasma cells 18%, and free light chain ratio 14 at the low-risk end of the spectrum must also, 18 months later, recognize the platform-generated alert that the 6-month surveillance results show M-protein 4.1 g/dL, plasma cells 24%, and free light chain ratio 23 crossing two of the Mayo 20/2/20 ultra-high-risk thresholds simultaneously, and must further integrate the pending whole-body MRI comparison where the radiologist has documented a new 6-mm focal lesion at the L3 vertebral body alongside the two previously documented 4-mm lesions now both measuring 5.5 mm — where the whole-body MRI simultaneously satisfies the myeloma-defining event criterion of ≥2 focal lesions ≥5 mm and requires immediate reclassification of the patient from SMM surveillance to active myeloma treatment initiation, and where the platform failure that prevents the hematologist from accessing the serial SPEP trend or the radiologist from posting the whole-body MRI comparison report at the moment when the clinical team is assembled in the tumor board to determine treatment versus continued surveillance allows the critical myeloma-defining event window to pass unrecognized. A bone marrow pathology platform unavailable when plasma cell quantification at the CD138-stained 200-cell differential count must resolve whether plasma cells are 58% (SMM) or 62% (myeloma-defining event requiring treatment), a free light chain documentation platform inaccessible when the ratio of 96 must be confirmed below or above 100 to determine whether a biomarker myeloma-defining event exists, a whole-body MRI management platform unavailable when new focal lesion development must be confirmed against the two-lesion myeloma-defining event threshold — these are not IT incidents. They are clinical disruptions at the diagnostic boundary between the highest-risk plasma cell surveillance state and active myeloma requiring immediate treatment, where the difference between correct and delayed recognition is measured in progression-free months and clinical consequences.
Uptime monitoring gives SMM tech teams the detection capability to identify platform failures within seconds, trigger immediate clinical workaround protocols, and demonstrate to myeloma programs, imaging departments, hematopathology laboratories, clinical trial sponsors, and compliance auditors that the platform's operational reliability matches the surveillance precision, imaging intensity, risk stratification complexity, and treatment readiness that ultra-high-risk SMM management demands.
Start monitoring your SMM care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #SmokeringMyeloma #SMM #myeloma #plasmacell #SPEP #freeLightChain #wholebodyMRI #PETCT #FISH #riskstratification #myelomaDefiningEvent #daratumumab #lenalidomide #REMS #AQUILA #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre